Key Takeaways:
- A new partnership between OPTEL and Kaster Technologies targets the operational gap between static production plans and the dynamic realities of the pharmaceutical plant floor.
- The combined solution integrates real-time line data with an AI optimization engine to create resilient schedules that adapt to constraints like equipment availability, staffing, and quality control.
- For manufacturers, the primary business impact is the potential to unlock hidden production capacity, stabilize workflows, and improve the use of critical resources in complex GMP environments.
Pharmaceutical manufacturers operate under constant pressure to increase output while adhering to strict Good Manufacturing Practices (GMP). This challenge is often compounded by legacy planning systems, such as rigid ERPs and spreadsheets, which struggle to adapt to the fluid nature of the production floor. When unexpected events occur—from equipment downtime to staffing changes—static schedules can quickly become obsolete, leading to reactive problem-solving and significant underutilization of valuable manufacturing capacity.
Addressing this industry-wide issue, traceability solutions provider OPTEL and AI software specialist Kaster Technologies have formed a strategic partnership. The collaboration aims to provide pharmaceutical companies with an intelligent production planning tool designed to bridge the gap between planning and execution. The solution pairs Kaster’s AI-powered planning engine with OPTEL’s validated, real-time manufacturing data.
"Production complexity in pharma is increasing, and traditional planning tools can no longer keep pace," says Alexandre Clarizio, Founder and CEO of Kaster Technologies. "By combining OPTEL's trusted, validated data with our advanced AI optimization, we deliver real-time production intelligence that helps manufacturers shift from reactive planning to predictive, performance-driven operations."
According to the companies, production schedules in many facilities often collapse within 48 hours due to an inability to reflect real-world operational constraints. The joint solution synchronizes strategic plans with on-the-ground conditions, enabling facilities to create resilient, data-driven operations. The companies report that this can help increase production capacity by up to 20% without requiring additional capital investment.
"Pharmaceutical manufacturers must produce more with the same resources while maintaining the highest standards of quality and compliance," says Louis Roy, Founder and CEO of OPTEL. "By partnering with Kaster Technologies, we extend the value of our solutions beyond traceability and compliance into intelligent production orchestration."
The production planning intelligence solution has already been implemented in live pharmaceutical environments, including a large sterile injectable manufacturing site in Canada. The companies reported that the deployment resulted in measurable gains in production capacity, workflow efficiency, and schedule stability. The system also helps optimize the use of critical resources such as equipment, personnel, and cleanrooms.
